Forma taps Novartis vet as new R&D chief; Ablynx extends pact with Merck;

@FierceBiotech: RaNA banks $55M to get its RNA drugs into the clinic. News | Follow @FierceBiotech

@JohnCFierce: Cara Therapeutics scores another positive PhII for lead opioid. More | Follow @JohnCFierce

@DamianFierce: The world is terrible. Article | Follow @DamianFierce

> Watertown, MA-based Forma Therapeutics has tapped Novartis ($NVS) vet John Hohneker as its new head of R&D. Hohneker most recently served as senior VP and global head of development for the immunology and dermatology franchise at Novartis. Release

> Ablynx has extended its pact with Merck ($MRK) to work on an increased number of immune checkpoint modulator targets. Release

> SutroVax, a spinout of Sutro Biopharma, raised $22 million in Series A cash to support its work on vaccines for infectious diseases. Story

> Gilead Sciences ($GILD) is touting positive Phase III results in a study testing whether an in-development, one-pill combination of four HIV treatments can measure up to its blockbuster Viread. The trial met its main goal of noninferiority, and the new pill notched a statistically significant improvement in patients with lower viral loads. More

Medical Device News

@FierceMedDev: Oxford Nanopore reels in $109M to ramp up R&D. FierceDiagnostics story | Follow @FierceMedDev

@StacyALawrence: iHealth expands its retail, connected medical device empire and looks to move into. Report | Follow @StacyALawrence

@VarunSaxena2: UPDATED: St. Jude to buy Thoratec for $3.4B, will pair its heart pump with the cardioMEMs patient monitor. Story | Follow @VarunSaxena2

@EmilyWFierce: Nonprofit snags $5.2M grant to investigate U.S. drug pricing. FiercePharma article | Follow @EmilyWFierce

> Bard hit with FDA warning letter affecting its vena cava filters. Report

> Harvard Wyss Institute spins out apnea prevention startup MediCollector. Article

Pharma News

@FiercePharma: NIAID scientists one step closer to 'universal' flu vaccine. More | Follow @FiercePharma

@CarlyHFierce: Earnings season is better than Christmas. I mean, I actually like most things better than Christmas, but point still stands. | Follow @CarlyHFierce

> Bristol-Myers smashes Q2 as hep C meds rake in overseas sales. Story

> Eli Lilly's Q2 beats the Street as newer products, animal health buy pitch in. Article

Vaccines News

> Pfizer talks up 'comprehensive' vaccines business. Report

> Health officials detail need for $2B vaccines fund. Item

> NIAID scientists one step closer to 'universal' flu vaccine. Article

> SutroVax bags $22M Series A to develop vaccines for infectious diseases. Story

> Sanofi's dengue vaccine anticipated on profitability 'high end.' More

CRO News

> Biocon might spin out its CRO after taking it public. More

> Huntingdon and Harlan raise up to $125M to fund their future together. News

> PRA doubles down on the hunt for new R&D talent. Report

> Covance and LabCorp open a new R&D center to pool their expertise. Story

> AMRI bets $174M on manufacturing with latest buyout. Article

Pharma Manufacturing News

> Sun may only get 3 of Ranbaxy's 4 banned plants ready for U.S. market. Item

> Capsugel expanding plant in Scotland. More

> Lupin gets first U.S. manufacturing base with buyout of GAVIS. Report

> Patheon, DPx unload chemical operations to tighten focus on pharma. Story

> Sandoz gives Novartis a boost, but 3 plants still get the boot. Article

Pharma Asia News

> From the pharma C-suite: Novartis on Asia, emerging markets in Q2. Item

> Lee family victory in Samsung shareholder challenge sets stage for biologics ramp up. Report

> India's drug and CRO manufacturing travails gather pace as New Delhi calls on diplomats to help. Article

> Industry groups lobby against Japan reimbursement price cuts. Story

> China state-owned drug firms move to direct consumer sales, prescriptions next? More

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.